VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
07 nov. 2023 08h00 HE
|
VYNE Therapeutics Inc.
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment...
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
01 nov. 2023 16h15 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
30 oct. 2023 07h20 HE
|
VYNE Therapeutics Inc.
Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritisFollowing completion...
VYNE Therapeutics Announces Private Placement of $88 Million
30 oct. 2023 07h05 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
30 oct. 2023 07h00 HE
|
VYNE Therapeutics Inc.
Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was...
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary,...
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 août 2023 08h00 HE
|
VYNE Therapeutics Inc.
Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential...
VYNE Therapeutics to Attend BIO International Convention
18 mai 2023 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary,...
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
11 mai 2023 16h01 HE
|
VYNE Therapeutics Inc.
Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202,...
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
01 mai 2023 08h00 HE
|
VYNE Therapeutics Inc.
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has demonstrated a potent anti-inflammatory and anti-fibrotic effect in...